News & Updates

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

27 Jun 2022

Among type 2 diabetes (T2D) patients on first-generation basal insulins (1BIs), a switch to either glargine or degludec in the real-world setting leads to marked improvements in glucose control without increasing the risk of hypoglycaemic events and weight gain, according to a study. Furthermore, the benefits seem to be comparable between the two second-generation basal insulins (2BIs).

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

27 Jun 2022

Revacept beneficial to patients with symptomatic ICA stenosis

26 Jun 2022

Patients with symptomatic internal carotid artery (ICA) stenosis may fare well with revacept, a competitive antagonist of glycoprotein VI, as the drug helps reduce the incidence of stroke or death, transient ischaemic attack, and bleeding complications, among others, according to a study.

Revacept beneficial to patients with symptomatic ICA stenosis

26 Jun 2022

$Add-on baclofen eases reflux in certain PPI-refractory GERD patients$

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

26 Jun 2022

In patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD), add-on treatment with baclofen improves several reflux parameters, but only among those who are positive for symptom association probability, a study has found.

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

26 Jun 2022

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

26 Jun 2022

Bleeding and mortality risks are elevated in atrial fibrillation (AF) patients treated with nonvitamin K antagonist oral anticoagulant (NOAC) who are also using P-glycoprotein (P-gp) and CYP3A4 inhibitors, reports a study, noting the need for close monitoring of these individuals.

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

26 Jun 2022

Novel oral neoadjuvant therapy shows promising phase II results

25 Jun 2022

The novel neoadjuvant therapy S-1, an oral fluoropyrimidine agent containing tegafur, gimeracil, and oteracil potassium, yields promising survival outcomes in high-risk patients with resectable pancreatic ductal adenocarcinoma, a recent study has found.

Novel oral neoadjuvant therapy shows promising phase II results

25 Jun 2022

Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults

25 Jun 2022 by

Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.

Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults

25 Jun 2022

PPIs raise death risk in advanced NSCLC patients on antitumour therapy

25 Jun 2022

Treatment with proton pump inhibitors (PPI) appears to increase the risk of mortality among patients with advanced nonsmall cell lung cancer (NSCLC) undergoing systemic antitumour therapy, reveals a recent study.

PPIs raise death risk in advanced NSCLC patients on antitumour therapy

25 Jun 2022

Tranexamic acid does not prevent haemorrhage-related events in Caesarean section

25 Jun 2022

Among women with multiple pregnancies, prophylactic treatment with tranexamic acid does not appear to reduce the incidence of blood loss-related events following caesarean delivery, a study has shown.

Tranexamic acid does not prevent haemorrhage-related events in Caesarean section

25 Jun 2022

Dabigatran continues to be safe, useful in NVAF patients during idarucizumab era

24 Jun 2022

Even after the dabigatran-specific reversal agent idarucizumab has been made available, dabigatran continues to be safe and well-tolerated for stroke and systemic embolism prevention in patients with nonvalvular atrial fibrillation (NVAF), reports a recent Japan study.

Dabigatran continues to be safe, useful in NVAF patients during idarucizumab era

24 Jun 2022

Maintenance niraparib a boon in advanced ovarian cancer

24 Jun 2022 by

Use of niraparib in the maintenance setting appears to minimize the risk of progression in advanced ovarian cancer patients, with surgical timing having little to no effect on the drug’s efficacy, as shown in a post hoc analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 study.

Maintenance niraparib a boon in advanced ovarian cancer

24 Jun 2022

News & Updates

Filter by Specialty:

Specialty:

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

Revacept beneficial to patients with symptomatic ICA stenosis

Revacept beneficial to patients with symptomatic ICA stenosis

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

Novel oral neoadjuvant therapy shows promising phase II results

Novel oral neoadjuvant therapy shows promising phase II results

Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults

Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults

PPIs raise death risk in advanced NSCLC patients on antitumour therapy

PPIs raise death risk in advanced NSCLC patients on antitumour therapy

Tranexamic acid does not prevent haemorrhage-related events in Caesarean section

Tranexamic acid does not prevent haemorrhage-related events in Caesarean section

Dabigatran continues to be safe, useful in NVAF patients during idarucizumab era

Dabigatran continues to be safe, useful in NVAF patients during idarucizumab era

Maintenance niraparib a boon in advanced ovarian cancer

Maintenance niraparib a boon in advanced ovarian cancer